Clinical Trial

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-08 -> 2026-07-30 2026-06-17
minor Completion pushed: 2026-05-08 -> 2026-07-30 2026-06-17
Trial Details
NCT Number NCT06873789
Lead Sponsor Incyte Corporation
Conditions Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Enrollment 9 participants
Start Date 2025-06-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-16